Eli Lilly, at a medical conference in Gothenburg, Sweden, presented interim data from 41 study participants who received Alzheimer’s treatment remternetug, reporting that the study showed that amyloid clearance was reached by 75% of the 24 patients who received remternetug at the three highest tested doses, reported Reuters’ Deena Beasley. The drugmaker is launching a Phase 3 study of the experimental antibody, but declined to comment on which doses will be selected for larger, later-stage trials, said Reuters, which quotes Dawn Brooks, Lilly’s global development leader for remternetug, as having said: "We are still trying to explore some of that." Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Viking Therapeutics price target raised to $31 from $20 at BTIG
- ‘Our Best Long-Term Picks’: Morgan Stanley Suggests 3 High-Quality Stocks to Buy Now
- Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
- Roche to collaborate with Lilly on early diagnosis of Alzheimer’s disease
- Stifel trims Biogen target, but has more confidence lecanemab ‘best-in-class’
